Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DF58YX
|
|||
| Drug Name |
AMG 133
|
|||
| Drug Type |
Antibody peptide conjugate
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66] | Phase 2 | [1] | |
| Company |
Amgen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Gastric inhibitory polypeptide receptor (GIPR) | Target Info | Antagonist/GLP1 agonist | [2] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Reactome | G alpha (s) signalling events | |||
| Glucagon-type ligand receptors | ||||
| WikiPathways | GPCRs, Class B Secretin-like | |||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05669599) A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus. U.S.National Institutes of Health. | |||
| REF 2 | An update on peptide-based therapies for type 2 diabetes and obesity. Peptides. 2023 Mar;161:170939. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.